CoChat

Lessons from a BACE1 inhibitor trial: Off‐site but not off base

Open access
Lahiri, Debomoy K., Maloney, Bryan, Long, Justin M., Greig, Nigel H. · 2014 · Alzheimer's & Dementia
Cited by 82

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is characterized by formation of neuritic plaque primarily composed of a small filamentous protein called amyloid‐β peptide (Aβ). The rate‐limiting step in the production of Aβ is the processing of Aβ precursor protein (APP) by β‐site APP‐cleaving enzyme (BACE1). Hence, BACE1 activity plausibly plays a rate‐limiting role in the generation of potentially toxic Aβ within brain and the development of AD, thereby making it an interesting drug target. A phase II trial of the promising LY2886721 inhibitor of BACE1 was suspended in June 2013 by Eli Lilly and Co., due to possible liver toxicity. This outcome was apparently a surprise to the study's team, particularly since BACE1 knockout mice and mice treated with the drug did not show such liver toxicity. Lilly proposed that the problem was not due to LY2886721 anti‐BACE1 activity. We offer an alternative hypothesis, whereby anti‐BACE1 activity may induce apparent hepatotoxicity through inhibiting BACE1's processing of β‐galactoside α‐2,6‐sialyltransferase I (STGal6 I). In knockout mice, paralogues, such as BACE2 or cathepsin D, could partially compensate. Furthermore, the short duration of animal studies and short lifespan of study animals could mask effects that would require several decades to accumulate in humans. Inhibition of hepatic BACE1 activity in middle‐aged humans would produce effects not detectable in mice. We present a testable model to explain the off‐target effects of LY2886721 and highlight more broadly that so‐called off‐target drug effects might actually represent off‐site effects that are not necessarily off‐target. Consideration of this concept in forthcoming drug design, screening, and testing programs may prevent such failures in the future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.11.004

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 82

Metadata

Authors
Lahiri, D. K., Maloney, B., Long, J. M., & Greig, N. H.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-02-14
Volume
10
Issue
5S
Pages
S411-9
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2120642977
Cited by
82
References
11
FWCI
5.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lessons from a BACE1 inhibitor trial: Off‐site but not off base. https://app.cochat.ai/papers/10.1016/j.jalz.2013.11.004
The paper
Lahiri, D. K., Maloney, B., Long, J. M., & Greig, N. H. (2014). Lessons from a BACE1 inhibitor trial: Off‐site but not off base. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.11.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.